Ascendis Pharma A/S
ASND
Rangering i aksjer
#1490
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Aksjekurs
$233.77
Markedsverdi
$14.58B
Endring (1 dag)
1.66%
Endring (1 år)
13.92%
Land
DK
Handel Ascendis Pharma A/S (ASND)
Kategori
Healthcare
Inntekter for Ascendis Pharma A/S (ASND)
Inntekter i Jun 2026 TTM: $119.93M
Ifølge Ascendis Pharma A/S sine nyeste økonomiske rapporter er selskapets nåværende resultat $119.93M. I 2024 hadde selskapet et resultat på $-388.38M, en økning sammenlignet med resultatet i 2023, som var $-524.15M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Ascendis Pharma A/S fra 2012 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $119.93M | -150.04% |
| 2025 | $-239.65M | -38.30% |
| 2024 | $-388.38M | -25.90% |
| 2023 | $-524.15M | -15.43% |
| 2022 | $-619.81M | 41.96% |
| 2021 | $-436.60M | -14.48% |
| 2020 | $-510.50M | 108.47% |
| 2019 | $-244.87M | 63.30% |
| 2018 | $-149.95M | 0.48% |
| 2017 | $-149.24M | 106.36% |
| 2016 | $-72.32M | 98.38% |
| 2015 | $-36.46M | 191.39% |
| 2014 | $-12.51M | -293.36% |
| 2013 | $6.47M | 281.71% |
| 2012 | $1.70M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | 4,298.37% |
US
|
|
| $-3.09B | -2,674.04% |
US
|
|
| $-4.02B | -3,448.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,526.51% |
NL
|
